Scancell Holdings updates on clinical trial of melanoma vaccine

Scancell Holdings said Tuesday it edged closer to completing clinical trials of a vaccine for the treatment of melanoma.

Scancell Holdings said Tuesday it edged closer to completing clinical trials of a vaccine for the treatment of melanoma.

The developer of therapeutic cancer vaccines recruited and treated the final patient in the second phase of tests for SCIB1, a DNA ImmunoBody injection.

The trial is being conducted in five UK centres in patients with Stage III/IV disease to assess the safety of the treatment and the immune response.

Patients are being treated with a 4.0mg dose of SCIB1, five times over six months.

Last month Scandell released findings from the first phase of the study which showed SCIB1 produced an immune response that may benefit patients with malignant melanoma.

At the same the group also announced approval from regulators to treat an extra group of patients with a higher 8.0mg dose of the vaccine.

"As expected, the recruitment of patients in the second part of the trial proceeded faster than recruitment for the first part of the trial, as we were not constrained by the cohort study design requiring sequential dose escalation, and there were more patients available with earlier stage disease," said Lindy Durrant, Joint Chief Executive Officer (CEO) of Scancell Holdings and Professor of Cancer Immunotherapy at Nottingham University.

"The recruitment and dosing of the final patient in part two gives us confidence that this phase of the study will be completed by the end of 2013, consistent with previous expectations."

Shares were down 0.59% to 42.25p at 9:19 Tuesday.

RD

Recommended

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework
Investment strategy

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework

John Stepek talks to Steve Clapham, investor, analyst and author of The Smart Money Method, about the dangers in picking individual stocks and why you…
8 Apr 2021
BP looks set to return more money to shareholders as it beats expectations
Energy stocks

BP looks set to return more money to shareholders as it beats expectations

Oil major BP is to embark on a share buyback programme after significantly reducing its debts. Saloni Sardana looks at what it means for your portfoli…
6 Apr 2021
Deliveroo has hit the market – but it’s not getting the warmest welcome
UK stockmarkets

Deliveroo has hit the market – but it’s not getting the warmest welcome

Food delivery company Deliveroo made its debut on the stockmarket this morning. But with the share price sliding by 30% straight away, it’s not made t…
31 Mar 2021
Three stocks to buy now that will come back stronger after Covid-19
Share tips

Three stocks to buy now that will come back stronger after Covid-19

Professional investor Ed Wielechowski of Odyssean Capital, chooses three compelling stocks that should thrive in a post-pandemic world.
29 Mar 2021

Most Popular

The bitcoin bubble will burst: here’s how to play it
Bitcoin

The bitcoin bubble will burst: here’s how to play it

The cryptocurrency’s price has soared far beyond its fundamentals, says Matthew Partridge. Here, he looks at how to short bitcoin.
12 Apr 2021
What does the Coinbase listing mean for bitcoin and other cryptocurrencies?
Bitcoin

What does the Coinbase listing mean for bitcoin and other cryptocurrencies?

As the bitcoin price hit new highs, the world's biggest cryptocurrency exchange, Coinbase, listed on the stockmarket. John Stepek looks at what that m…
15 Apr 2021
Properties for sale for around £400,000
Houses for sale

Properties for sale for around £400,000

From a converted church in Banffshire with views towards the Cairngorms National Park, to a period property in the Georgian market town of Beverley, e…
2 Apr 2021